Trial Profile
Yokohama Add-on Inhibitory efficacy of Dapagliflozin on Albuminuria in Japanese patients with type 2 diabetes study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Jun 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms Y-AIDA
- 14 Apr 2021 Results of sub-group analysis assessing differences in home BP lowering effects between high and low dietary salt intake patients with albuminuric diabetic kidney disease, presented at the Joint Meeting of the European Society of Hypertension and International Society of Hypertension..
- 26 Jul 2019 Status changed from active, no longer recruiting to completed.
- 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.